Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16596109 | 0.74 | EGFR (0.35) | EGFRFLT1CYP2A6PARP1 | |
| SCHEMBL1497985 | 0.74 | PDPK1 (0.40) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3842031 | 0.72 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5245809 | 0.72 | GPR84 (0.33) | CYP2A6 | |
| SCHEMBL390375 | 0.70 | PARP1 (0.46) | CYP2A6PDPK1PARP1 | |
| SCHEMBL3840990 | 0.69 | CYP1A2 (0.54) | CYP1A2CYP2C19KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL391441 | 0.68 | PARP1 (0.44) | CYP2A6PDPK1PARP1 | |
| SCHEMBL17786637 | 0.68 | KDM4E (0.38) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10054251 | 0.68 | CYP2A6 (0.41) | CYP1A2CYP3A4CYP2A6ALDH1A1 | |
| SCHEMBL3840992 | 0.66 | HSD17B10 (0.35) | CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833830-B1 | QUINOLINE DERIVATIVE, USE AND PRODUCTION THEREOF, AND DRUG CONTAINING THE SAME | BAYER SCHERING PHARMA AG (DE) | 2009-10-14 | — | — | EP | disclosed |
| EP-1833830-A1 | QUINOLINE DERIVATIVE, USE AND PRODUCTION THEREOF, AND DRUG CONTAINING THE SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060167035-A1 | Quinoline derivative, its use, production and pharmaceutical agents containing the latter | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066955-A1 | QUINOLINE DERIVATIVE, USE AND PRODUCTION THEREOF, AND DRUG CONTAINING THE SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167035-A1 | Quinoline derivative, its use, production and pharmaceutical agents containing the latter | NQO2, RECQL, XDH | CYP1A2 8/4885CYP3A4 100/4885CYP2D6 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.